16+
Major trials tracked
Targeted & bispecific oncology · Live ClinicalTrials.gov data
Amivantamab (Rybrevant) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 amivantamab trials on ClinicalTrials.gov by enrolment, 8 of them actively recruiting. The next phase 3 primary completion among them is expected Dec 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.
7
Phase 3 trials
8
Actively recruiting
Dec 2027
Next phase 3 primary completion
7,659
Participants across trials
Janssen Research & Development, LLC
Lead sponsor by trial count
amivantamab (16)16 active2018–2031
amivantamab
'18
'20
'22
'24
'26
'28
'30
amivantamab
BoBP2
MARIPOSAP3
PAPILLONP3
MARIPOSA-2P3
PALOMA-3P3
PALOMA-2P2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)P2
COCOONP2
OrigAMI-2P3
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)P2
OrigAMI-3P3
COPERNICUSP2
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.P2
OrigAMI-5P3
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune SystemP2
AmiCAREP4
Upcoming readouts
10 ahead · amivantamab
Select a trial to load its full ClinicalTrials.gov record.
Key amivantamab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07469488 | AmiCARE — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients W… | Phase 4 | Not yet recruiting | Aug 2029 |
| NCT06750094 | OrigAMI-3 — A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and… | Phase 3 | Recruiting | Dec 2027 |
| NCT06662786 | OrigAMI-2 — A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatmen… | Phase 3 | Recruiting | Dec 2028 |
| NCT07276399 | OrigAMI-5 — A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants Wi… | Phase 3 | Recruiting | Jun 2029 |
| NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, i… | Phase 3 | Active, not recruiting | May 2023 |
| NCT04988295 | MARIPOSA-2 — A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-B… | Phase 3 | Active, not recruiting | Jul 2023 |
| NCT04487080 | MARIPOSA — A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic… | Phase 3 | Active, not recruiting | Aug 2023 |
| NCT05388669 | PALOMA-3 — A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With… | Phase 3 | Active, not recruiting | Jan 2024 |
| NCT03767075 | BoB — A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | Phase 2 | Recruiting | May 2025 |
| NCT05845450 | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | Phase 2 | Recruiting | May 2026 |
| NCT05498428 | PALOMA-2 — A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Fac… | Phase 2 | Recruiting | Aug 2027 |
| NCT06116682 | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expan… | Phase 2 | Recruiting | May 2028 |
Related drug pipelines
FAQ
- How many clinical trials are running for amivantamab?
- ClinicalTrials.gov lists more than 16 phase 2–4 amivantamab trials. This page tracks the 16 largest by enrolment: 8 phase 2, 7 phase 3, and 1 phase 4 among them, with 8 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare amivantamab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.